Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)
Summary
- This real-world study of US patients with platinum-resistant ovarian cancer (PROC) showed that nab-paclitaxel had comparable effectiveness and a lower rate of neuropathy compared with paclitaxel monotherapy.
- Nab-paclitaxel is an effective treatment option for patients with PROC and is a valid comparator for clinical trials in PROC.